Barclays
ORKA

Barclays’s Oruka Therapeutics ORKA Stock Holding History

Barclays’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.12M Sell
74,762
-10,975
-13% -$731K ﹤0.01% 1657
2026
Q1 		$4.21M Sell
85,737
-87,592
-51% -$3.04M ﹤0.01% 1926
2025
Q4 		$5.25M Buy
173,329
+77,999
+82% +$2.17M ﹤0.01% 2179
2025
Q3 		$1.83M Buy
95,330
+4,166
+5% +$61.8K ﹤0.01% 2949
2025
Q2 		$1.02M Buy
91,164
+15,831
+21% +$165K ﹤0.01% 3326
2025
Q1 		$773K Buy
75,333
+750
+1% +$9.35K ﹤0.01% 3260
2024
Q4 		$1.45M Buy
+74,583
New +$1.82M ﹤0.01% 3129
2023
Q2 		– Sell
-4
Closed -$98 – 5160
2023
Q1 		$98 Buy
+4
New +$105 ﹤0.01% 4997
2018
Q2 		– Hold
0
– – – 7347
2018
Q1 		– Hold
0
– – – 7387

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Barclays's ORKA Position: Q2 2026 in Review

Barclays reduced its Oruka Therapeutics (ORKA) stake by 13% in Q2 2026, selling an estimated $731K and leaving 74,762 shares worth $7.12M. The position accounts for ﹤0.01% of the portfolio, ranked #1657.

Barclays first reported a position in ORKA in Q1 2023 and has held it in 8 quarters since. 255 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Barclays held 74,762 shares of Oruka Therapeutics worth $7.12M as of Q2 2026.
  • Barclays sold 10,975 Oruka Therapeutics shares in Q2 2026, an estimated $731K.
  • Oruka Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1657 holding.
  • Barclays first reported a position in Oruka Therapeutics in Q1 2023 and has held it in 8 quarters since.
  • 255 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.